Liisa Bayko

Yasmeen Rahimi

Annabel Samimy

Jasmine Fels

Mayank Mamtani

Patrick Trucchio

Roger Song

Andy Hsieh

Andy Shah

Catherine Okoukoni

Corinne Johnson

Dominic Risso-Gill

Ellie Merle

Jayed Momin

Jonathan Wolleben

Karin Johnson

William Wood

Xiaotong Jia

- Altimmune is developing **pemvidutide**, a dual GLP-1 glucagon receptor agonist, as a potential treatment for **Metabolic Dysfunction Associated Steatohepatitis (MASH)**, combining direct liver effects with metabolic benefits.  **[0001326190_2193209_0]** 
- The Phase 2b IMPACT trial demonstrated **class-leading MASH resolution of approximately 59% of patients at 24 weeks**, significant weight loss, and favorable tolerability with the lowest rates of adverse event discontinuations among incretins.  **[0001326190_2193209_1]** **[0001326190_2193209_2]** **[0001326190_2193209_3]** 
- Key upcoming milestones in the **fourth quarter** include the **48-week data readout** from the IMPACT trial and an **end-of-Phase 2 meeting with the FDA** to discuss the Phase 3 program, which is planned for **2026**.  **[0001326190_2193209_0]** **[0001326190_2193209_5]** 
- The company aims for a flexible Phase 3 design to adapt to potential regulatory changes regarding the use of non-invasive tests (NITs) as a replacement for biopsies, positioning pemvidutide for a broad commercial opportunity across MASH fibrosis stages.  **[0001326190_2193209_2]** **[0001326190_2193209_4]**

Altimmune Provides Update on Pemvidutide for MASH Ahead of Key Milestones

- Altimmune is advancing **pemvidutide**, a dual GLP-1/glucagon receptor agonist, as a potential best-in-class treatment for **metabolic dysfunction-associated steatohepatitis (MASH)**.  **[0001326190_2193168_0]** 
- The **Phase 2b IMPACT trial** demonstrated **class-leading MASH resolution** in **59% of patients at 24 weeks**, along with **greater than 6% weight loss** and approximately **50% normalization of liver fat**.  **[0001326190_2193168_1]** 
- Pemvidutide showed the **lowest rates of adverse event discontinuations** among incretins, highlighting its favorable tolerability profile.  **[0001326190_2193168_4]** 
- Key upcoming milestones in **Q4 2025** include the **48-week data readout** from the IMPACT trial and an **end of phase 2 meeting with the FDA**, with plans to move into **Phase 3 in 2026**.  **[0001326190_2193168_0]** **[0001326190_2193168_6]**

Altimmune Provides Update on Pemvidutide for MASH Treatment

- The Portnoy Law Firm announced a **class action lawsuit** on behalf of Altimmune, Inc. (NASDAQ: ALT) investors who purchased securities between **August 10, 2023, and June 25, 2025**.  **[1326190_a171533073584bdfb35179c7710ffbf0_0]** 
- The lawsuit stems from Altimmune's announcement on June 26, 2025, regarding topline results from its IMPACT Phase 2b MASH trial of Pemvidutide, which **failed to achieve statistical significance** in the fibrosis reduction primary endpoint due to a higher-than-expected placebo response.  **[1326190_a171533073584bdfb35179c7710ffbf0_0]** 
- Following this news, Altimmune’s stock price **fell $4.10 per share, or 53.2%**, closing at **$3.61 per share on June 26, 2025**.  **[1326190_a171533073584bdfb35179c7710ffbf0_0]** 
- Investors have until **October 6, 2025**, to file a lead plaintiff motion.  **[1326190_a171533073584bdfb35179c7710ffbf0_0]**

Altimmune Faces Class Action Lawsuit Following Trial Results

- Altimmune's GLP-1/glucagon dual agonist, pemvidutide, demonstrated **class-leading MASH resolution** at 24 weeks in Phase 2 data, alongside **robust weight loss of approximately 6%** and excellent tolerability without dose titration.  **[1326190_2162483_0]** **[1326190_2162483_2]** 
- The company is in discussions with the FDA regarding the acceptance of **AI-enabled histological assessments for fibrosis** and plans a flexible Phase 3 design that could adapt to non-biopsy trial requirements.  **[1326190_2162483_1]** **[1326190_2162483_4]** 
- Altimmune anticipates releasing **12-month data in the fourth quarter**, expecting continued improvement in non-invasive tests (NITs) and weight loss, which will guide the Phase 3 trial design.  **[1326190_2162483_3]** 
- Pemvidutide is strategically positioned as a **single molecule providing both direct liver effects and metabolic benefits** for MASH, aiming to differentiate from combination therapies and semaglutide.  **[1326190_2162483_5]** **[1326190_2162483_6]** 
- The company also has **Fast Track status for alcohol use disorder (AUD)**, with an ongoing trial expected to provide a readout in the **second half of 2026**.  **[1326190_2162483_7]**

Altimmune Provides Update on Pemvidutide MASH Program and Pipeline

- Faruqi & Faruqi, LLP is investigating **Altimmune, Inc.** for potential securities claims.  **[1326190_110fec4f7461474fb895f5a68eb4f43c_1]** 
- The investigation covers investors who suffered losses between **August 10, 2023, and June 25, 2025**.  **[1326190_110fec4f7461474fb895f5a68eb4f43c_0]** 
- A federal securities class action has been filed against Altimmune, with a deadline of **October 6, 2025**, for investors to seek the role of lead plaintiff.  **[1326190_110fec4f7461474fb895f5a68eb4f43c_1]** 
- The lawsuit alleges that Altimmune's stock price declined by **53.2%** on **June 26, 2025**, falling from **$7.71 to $3.61 per share**, after the company announced that its IMPACT Phase 2b MASH trial of Pemvidutide failed to achieve statistical significance for fibrosis reduction.  **[1326190_110fec4f7461474fb895f5a68eb4f43c_1]**

Faruqi & Faruqi Investigates Altimmune Following Stock Decline

- Berger Montague PC is investigating potential securities fraud claims against **Altimmune, Inc. (NASDAQ: ALT)**.  **[1326190_ec788fcae1b744b7b235454bacfe7552_0]** 
- The lawsuit covers investors who purchased Altimmune securities between **August 10, 2023, and June 25, 2025**, the designated Class Period.  **[1326190_ec788fcae1b744b7b235454bacfe7552_0]** 
- The claims stem from Altimmune's **June 26, 2025**, announcement that its IMPACT study failed its primary endpoint, which led to a **53%** stock plunge from **$7.71** to **$3.61** per share.  **[1326190_ec788fcae1b744b7b235454bacfe7552_0]** 
- Investors have until **October 6, 2025**, to seek appointment as a lead plaintiff representative.  **[1326190_ec788fcae1b744b7b235454bacfe7552_0]**

Berger Montague Investigates Altimmune for Securities Fraud

- Faruqi & Faruqi, LLP is investigating potential claims against **Altimmune, Inc.**, related to a federal securities class action that has been filed against the company.  **[1326190_20250924NY81599:0]** 
- The investigation follows a **53.2% decline** in Altimmune's stock price on **June 26, 2025**, after the company announced that its Pemvidutide MASH trial failed to achieve statistical significance in the fibrosis reduction primary endpoint.  **[1326190_20250924NY81599:0]** 
- Investors who suffered losses exceeding **$75,000** between **August 10, 2023, and June 25, 2025**, are encouraged to contact the firm, with the deadline to seek the role of lead plaintiff being **October 6, 2025**.  **[1326190_20250924NY81599:0]**

Altimmune Faces Securities Class Action Lawsuit

- Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. and has filed a federal securities class action lawsuit.  **[1326190_041c87e1598140d49364d2df545669ec_1]** 
- The lawsuit stems from Altimmune's announcement on **June 26, 2025**, that its **IMPACT Phase 2b MASH trial of Pemvidutide** failed to achieve statistical significance in the fibrosis reduction primary endpoint.  **[1326190_041c87e1598140d49364d2df545669ec_1]** 
- Following this news, Altimmune's common stock price **declined dramatically**, falling **53.2%** from **$7.71 per share on June 25, 2025**, to **$3.61 per share on June 26, 2025**.  **[1326190_041c87e1598140d49364d2df545669ec_1]** 
- Investors who purchased securities between **August 10, 2023, and June 25, 2025**, are covered by the lawsuit, and the deadline to seek the role of lead plaintiff is **October 6, 2025**.  **[1326190_041c87e1598140d49364d2df545669ec_0]** **[1326190_041c87e1598140d49364d2df545669ec_1]**

- Faruqi & Faruqi, LLP is investigating **Altimmune, Inc. (NASDAQ: ALT)** for potential claims in a federal securities class action.  **[1326190_689cc168763349d48fa4b7522d69fef1_1]** 
- The investigation follows a **53.2%** stock price decline on **June 26, 2025**, after the company's IMPACT Phase 2b MASH trial of Pemvidutide failed to achieve statistical significance in its fibrosis reduction primary endpoint.  **[1326190_689cc168763349d48fa4b7522d69fef1_1]** 
- Investors who suffered losses exceeding **$75,000** between **August 10, 2023, and June 25, 2025**, are encouraged to contact the firm.  **[1326190_689cc168763349d48fa4b7522d69fef1_0]** 
- The deadline for investors to seek the role of lead plaintiff in the class action is **October 6, 2025**.  **[1326190_689cc168763349d48fa4b7522d69fef1_1]**

Altimmune (ALT)